Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
2(29%)
Results Posted
100%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_3
2
29%
Ph phase_2
4
57%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Completed2
unknown1
Withdrawn1
Recruiting1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
2
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (66.7%)
Phase 32 (33.3%)

Trials by Status

unknown114%
withdrawn114%
recruiting114%
terminated114%
active_not_recruiting114%
completed229%

Recent Activity

2 active trials
Showing 5 of 7
unknown

Managed Access Programs for CTL019, Tisagenlecleucel

NCT03601442
recruitingphase_3

Study of Out of Specification for Tisagenlecleucel

NCT04094311
active_not_recruitingphase_2

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

NCT03876769
completedphase_2

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

NCT02435849
terminatedphase_2

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

NCT04161118
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03601442

Managed Access Programs for CTL019, Tisagenlecleucel

Unknown
NCT04094311Phase 3

Study of Out of Specification for Tisagenlecleucel

Recruiting
NCT03876769Phase 2

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Active Not Recruiting
NCT02435849Phase 2

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Completed
NCT04161118Phase 2

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Terminated
NCT03123939Phase 3

Phase III B in Acute Lymphoblastic Leukemia

Completed
NCT02167360Phase 2

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7